ASCL1 and small cell lung carcinoma: CBL0137 treatment in SCLC prevents SP3 binding to the NOTCH1 promoter, decreases achaete-scute homolog-1 (ASCL1) expression, increases the mRNA expression of NOTCH1, and inhibits CSC renewal.